Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, has officially announced the launch of a comprehensive new microbiome research solution.
According to certain reports, the stated solution arrives bearing an ability to integrate metagenomics sequencing and bioinformatics tools with a new microbiome metabolite panel, all for creating the industry’s most powerful microbiome research toolkit.
To understand the significance of such a development, we must take into account how, even though metagenomics can very well identify microbial species and their genetic potential, it does not reveal their functional contributions. This is particular evident for metabolic activities and bioactive compounds that microbes produce capable of impacting the host.
In response, Metabolomics, which measures the collection of small molecules in a sample, addresses this need through a phenotypic snapshot of microbiome activity. For better understanding, Metabolites are critical mediators, designed to link microbial functions with host physiology, immune responses, and disease progression.
Anyway, more on Metabolon’s new microbiome research solution would reveal how it brings forth a user-friendly toolkit geared towards supporting novel computational approaches that can rapidly address complex biomedical research and precision medicine challenges.
Talk about the whole value proposition on a slightly deeper level, we begin from its promise to provide an assortment of high-quality metagenomic sequencing options which make it possible for customers to select different sequencing methods and depths, integrating metagenomics data seamlessly with metabolomic and phenotypic data.
Next up, we have a new microbiome panel focused on hundreds of metabolites so to provide comprehensive insights into the microbiome. Not just that, customers may also combine metagenomics sequencing options and bioinformatics tools with Metabolon’s industry-leading Global Discovery Panel.
Complementing that would be an assortment of easy-to-use microbiome bioinformatics tools that will appeal to both expert and aspiring microbiome researchers.
These tools, on their part, include gold-standard bioinformatics pipelines for processing raw shotgun and 16S sequencing data to answer critical research questions like “How does the microbial community differ in composition across my samples and groups, and in an unsupervised approach, what microbial groups are important among my samples?”
Beyond that, there is a machine learning-driven integration which can effectively uncover multiomic relationships between microbial community composition and metabolic profiles, revealing phenotype-associated biomarkers and novel associations between microbes and metabolites.
Founded almost 25 years ago, Metabolon’s rise up the ranks stems from delivering biochemical data and insights that expand and accelerate the impact of life sciences research, while simultaneously supporting other ‘omics’ technologies. The company’s portfolio of solution, at present, provides scalable, customizable multiomics solutions, including metabolomics and lipidomics, each one revolving around fulfilling customer needs, right from discovery through clinical trials and product life-cycle management.
Metabolon’s excellence can also be understood once you consider it currently boasts 15,000+ client projects, 3,500+ scientific publication references, and ISO 9001:2015, CLIA, and CAP certifications.
“Metabolon is now a one-stop shop for high-quality metagenomics and metabolomics data, integrated and visualized within an easy-to-use bioinformatics platform,” said Dr Karl Bradshaw, Chief Business Officer at Metabolon. “This synergy enables deeper microbiome insights than possible with either approach individually. Metabolomics is an essential companion to metagenomics and rapidly reveals the biological impact of microbiome variations.”
